Prednisolone 25 2018 report



Prednisolone 25 2018 U.S. PROMOTIONAL AUDIT REPORT

Published July 2019 • 21 Pages

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Prednisolone 25 through reportable promotional activity in 2018 and how does this compare to its peer set in the Allergic Rhinitis market?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
  • How does Mission’s depth of coverage vary within key specialties (e.g., Pediatric Medicine, Family Medicine, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Prednisolone 25 throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Prednisolone 25 in 2018?

Data Sources and Methodology:

  • MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 1,100 paid interactions across 800 physicians made on behalf of Prednisolone 25 were carefully examined to support our analysis. In addition, interaction data from 6 peer products (e.g. Dymista, Grastek, Karbinal ER, Odactra, Oralair, and Ragwitek ) was leveraged to provide benchmarking and market insights.